ENGN
enGene TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
+
Peers tracked
11
U.S. public peers
Grade Position
Above peers
vs peer average
ENGN vs peer average
78/100
ENGN vs. peer average (B vs. D)
Grade spread
A 1 · B 1 · C 3 · D 1 · F 5
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
CGON is the first available peer comparator.
CG Oncology is the closest public clinical comparator because cretostimogene is being developed in BCG-unresponsive NMIBC with CIS, so its efficacy and durability bar is the cleanest read-through for what investors will demand from detalimogene.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
ENGN
enGene Therapeutics
CGON
CG Oncology
Grade
B
C
Momentum
46
85
Value
57
41
Sentiment
59
36
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Mixed
Grade position vs CGON
ENGN / CGON
Grade Position
Above peers
ENGN vs. peer average (B vs. D)
78/100
Momentum
46
CGONValue
57
ENGNSentiment
59
ENGNRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs ENGN
CGON is the first peer returned for this comparison set.